Dr. Nermarie Velazquez, MD

Dr. Velazquez practices at Bon Secours Charity Health System Medical Group in Warwick, New York.

Dr. Velazquez's NPI, 1093192411, was assigned on May 5, 2015. Dr. Velazquez graduated from Duke University School Of Medicine in 2015. Dr. Velazquez holds New York license 311254.

Dr. Velazquez's primary practice is Bon Secours Charity Health System Medical Group, at 20 Grand St, Warwick, NY 10990 in Orange County. The practice phone is (845) 987-3906.

Dr. Velazquez's primary practice is Bon Secours Charity Health System Medical Group in Warwick, New York. Dr. Velazquez is also affiliated with St. Anthony Community Hospital. The medical group on file is Westchester Medical Center Advanced Physician Services. Dmand AI also links Dr. Velazquez to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Velazquez practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Velazquez's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Velazquez's licenses on file in 2 states: New York and New Jersey.

CMS data shows 1,671 Medicare services from Dr. Velazquez across 12 procedure codes in 2024, for 437 Medicare patients. Medicare paid $98,274 for them.

CMS counts 437 Medicare patients who saw Dr. Velazquez in 2024. The largest group is 75 to 84, with 177 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Velazquez's median patient age at 72, with 61% women.

In 2024, Dr. Velazquez wrote 1,125 Medicare Part D claims for 341 patients. 70% of them were for generic drugs. CMS names the drug for 1,008 of them, across 19 drugs with 11 or more claims each, at $235,968 in total drug cost. In 2023, CMS named 654 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Velazquez for performance year 2024, reported through an alternative payment model (APM). Dr. Velazquez accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Velazquez as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Velazquez, published from 2018 to 2022. 2018 was the busiest year, with 2. The most frequent topics are Biopsy, Carcinoma, Renal Cell and Kidney Neoplasms. Dr. Velazquez has published most often in Clin Genitourin Cancer. Dr. Velazquez's most frequent co-authors are Marc Andrew Bjurlin, DO, Stella K. Kang, MD and Jamie Michael.

CMS Open Payments shows 20 general payments to Dr. Velazquez from 12 drug and device companies from 2020 to 2025. Grants make up the largest share, 97% of the total. Boston Scientific Corporation paid the most, $30,528.

Dr. Velazquez graduated from Duke University School Of Medicine in 2015.